COVID-19 neutralizing monoclonal antibody (mAb) is used for treating COVID-19 positive patients who are non-hospitalized due to COVID-19 and/or at high-risk for progressing to severe COVID-19.
High Risk Criteria
Adults: Patients ≥ 18 years of age who meet at least one of the following criteria
Pediatrics: Patients 12–17 years old (weighing ≥ 40kg) who meet at least one of the following criteria
Mild to Moderate Symptoms
Mild signs and symptoms
Moderate COVID-19 illness
Additional Info …
Why use neutralizing mAbs in high-risk patients with COVID-19?
What are the risks of neutralizing mAb infusions that I should discuss with my patients?
How long will it take for my patients to receive the neutralizing mAb infusion?
Where can I send my patients to get a neutralizing mAb infusion?
Will my patients have to pay for this infusion?
If my patient is vaccinated and tests positive for COVID-19, can they still receive neutralizing mAb treatment?
Can COVID-19 vaccine be given to patients who have received neutralizing mAbs for treatment of COVID-19?
Emergency Use Authorization (EUA)
Sandra Schneider, MD, FACEP Sam Shahid, MBBS, MPH
Questions, Contact us today!
Supported by a contribution from Lilly.
The American College of Emergency Physicians (ACEP) makes every effort to ensure that contributors and editors of its resources are knowledgeable subject matter experts and that they used their best efforts to ensure accuracy of the content. However, it is the responsibility of each user to personally evaluate the content and judge its suitability for use in his or her medical practice in the care of a particular patient. Users are advised that the statements and opinions expressed in this resource are provided as recommendations of the contributors and editors at the time of publication and should not be construed as official College policy. ACEP acknowledges that, as new medical knowledge emerges, best practice recommendations can change faster than published content can be updated. ACEP recognizes the complexity of emergency medicine and makes no representation that this resource serves as an authoritative resource for the prevention, diagnosis, treatment, or intervention for any medical condition, nor should it be used as the basis for the definition of or the standard of care that should be practiced by all health care providers at any particular time or place. To the fullest extent permitted by law, and without limitation, ACEP expressly disclaims all liability for errors or omissions contained within this resource, and for damages of any kind or nature, arising out of use, reference to, reliance on, or performance of such information.
Copyright 2021, American College of Emergency Physicians, Dallas, Texas. All rights reserved. Produced in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this resource may be reproduced or distributed in any form or by any means or stored in a database or retrieval system without prior written permission of the publisher.
Requests for permission should be sent here.